balance Well, revenue overview thank And I our brief you, cover will results And what strong opening during agenda remarks. Brian. we remarks, of the a prepared our for fourth with an Raul with start me will let my quarter. start of will after financial condition provide our in-depth review and and a of quarterly our well XXXX financial more introduced as XX, we as as a you guidance results summary in of December today's formal of for release press with the financial XXXX. that sheet
we call the that, for your open questions. will Following
beginning Now our fourth quarter, revenue year-over-year. fourth of $XXX GAAP in total X% up the reported of quarter revenue performance, we with million a review
sales. international driven growth and in Our by total the X% in X% revenue US was growth growth GAAP
basis Our compared rates X% in headwind increased the constant total organic an our year to to the on in prior revenue changes exchange related currency excluding revenue period. year-over-year to growth quarter fourth GAAP the
in results growth revenue discussed We delivered three we end quarter that constant our currency at high of call. our expectations the earnings
of for the in in X% the constant range to fourth expectations revenue our X% shared currency quarter. year-over-year we Specifically, growth
line that growth driven team the than our call. United international results currency with of more quarter in Quarter And were sales were expectations trend, from execution the anticipated favorable in EMEA outlined primarily third a four in was by region. particularly in and constant solid a States result revenue the we our demand
fourth the more growth rates detailed a results all our Note, each in me the stated, performance currency of otherwise with our and basis. are sales let provide on categories. reportable with Now, unless primary of revenue product quarter, approximated you beginning review in year-over-year our constant
included related item our release available press website. our from the results non-GAAP have GAAP presentation and to reported in reconciliations We on our
driven QX fourth our Now total X% segment. in X% by exceeded of a partially range and growth intervention Endoscopy of our Cardiovascular growth products came segment quarter our high-end four. offset Sales growth Cardiovascular decline revenue expectations growth was increased by our in our largest Endoscopy the quarter segment of X%, again expectations the this growth peripheral quarter. in driver of within total the cardiovascular representing in in
increased total sales PI four. product XX% PI XX% products our low and and the sales biopsy localization and increased in growth geography of and of and year-over-year roughly roughly and quarter the XX% access double-digits radar respectively, represented products together of total and Within represented XX% growth category, together in embolics each PI our of our our
Within product of XX% invention of increased EP segment contributors products. fourth quarter business, largest of in growth and products, XX% in three year-over-year. the growth interventional largest sales Cardiac contributor our cardiovascular intervention CRM growth sales cardiac products, X% sales sales representing were the in in growth XX% second to the total angiography the QX in
strong strong was products inquired our PhD products for Snap products quarter sheath valve and of product growth driven and growth by our in growth CRM was growth guidewires. by by driven Angiography our HeartSpan driven our demand impressive hemostatic demand was diagnostic results Intervention EP another for sheath.
products in continued categories OEM including we XX% products. improving the expectations larger of our coatings, in multiple QX, merit customers increased attribute kits angiography our of Sales to which exceeding from and demand high-end
Endoscopy in and with assumptions supporting Finally, of sales growth range both our sales the line decreased expectations. our which QX revenue of segment X% largely were of products our CPS X% increased in
a basis. to Now our performance geographic of summary a brief sales on turning
Sales of in our constant Our quarter. fourth the total quarter sales of increased our midpoint came customers represented company currency X% expectations growth year-over-year. in US at the growth and to XX% this US
macro challenging XX% regions environment increased in above our the growth the certain in quarter or strong sales high-end of posted fourth high-end the is All at performance the major QX. global in of International international our specifically. expectations in year-over-year, markets three of which light
increased world XX% respectively the regions Sales of in X% EMEA, XX%, APAC and the and rest year-over-year.
all three QX, driven demand Kingdom in by upside the Europe. Germany, expectations versus region the most and in from regions Eastern primarily strong United While we the France, were EMEA saw
also by purchasing. offsetting in was growth PI high growth driven seeing product, where to growth for to in growth which related APAC volume-based continued Low the in in China, CI primarily APAC and than headwinds demand QX. strong single-digit we is are more double-digit region Japan contributed strong the
in growth in and by growth we declines prior And Brazil offset in Mexico lastly in by Latin and region, world year-over-year, high was of compared XX% also Canada the partially mid-teens America growth year rest X% our ahead delivered which the period. expectations of single-digit to driven
growth the by strong despite trends our another and part encouraged in execution we're international of marked by quarter markets. particularly team's environment summary, In operating a solid challenging
call comment other to quarter. want to I a Now over items before Raul, noteworthy the in turning on the few
cash in First, we delivered another quarter and of flow profitability expansion generation improvement, QX. free margin
operating gross and non-GAAP net QX. profit non-GAAP XX% X% profit, year-over-year, and Our X%, increased income non-GAAP in respectively
points quarter. XXXX. a of we've flow that results quarter performance Our generated the non-GAAP financial year-over-year operating year believe continuation basis the We throughout delivered represent margin $XX.X increased million to fourth in XX.X% our in fiscal free the cash we of and strong XX
are Importantly, and growth enhancing this Merit's our we results we profitability financial believe long-term executing evidence towards of year goal our profile. represent clear that
$XX more a constant nearly generated we our than cash revenue profile of XX% fiscal margin, free flow year-over-year non-GAAP Specifically delivered in XXXX, X% we growth, year basis point currency with profitability strong million. improvement in a improvements operating XX and
We than three-year at least remain committed cumulative to XXXX we at the that for of currency margins XX% outlined at which ending flow the generated $XXX period cash December XX, increase and for financial constant Foundations CAGR way by of free reminder non-GAAP the the in least of a to program X%, revenue million. targets a Growth organic for more operating called
highlight execution FDA new Second, XXXX. a of breakthrough our proud the releases and clearance XXXX, specifically XXX team has via and FDA. where products. from the in and clearance development, fiscal strong commercialization one including a of continued the Throughout our of new product commercialization team's highlighted another eight I the progress in designation of new been to of to well products towards commitment strategic launches, I'm initiatives areas press our executing we development, clearance wanted key year the area
body Finally, the evidence we to also made our progress product. initiative of in recent expand clinical towards our months strategic for
circuits our continues the of to study WAVE WRAPSODY outflow investigational Stent the occlusion Specifically, for an Graft, clinical study, Endovascular progress. studied device of dialysis within or stenosis the treatment being
We the the as clinical sites actively the enrollment full of and have end quarter three quarter begin of enrollment first were cohort XX in enrolling targeting well. pleased to fourth we in are of We by XXXX. Brazil patients
patients already -- in selected XX the blockage design blood with these excuse The use with stenosis clinical Endoprosthesis WRAPSODY world. a benefits vessels me a or association in is of WRAP that patients half for hemodialysis or have around sites enrolling Roughly required sites in of receiving of underway evaluate to XX study narrowing experience dialysis. associated Cell-Impermeable the countries the study been
is a and guidance system registry through the diagnosing and the in this breast The to workflow centers towards months in study coming surgical utility the StreamLock demonstrate progressing Canadian treating SCOUT to intended working of for selection study phase site and Canadian start-up efficiency are we improve cancer.
The embolization represents that gelatin in patients to populations embolic designed diverse is and agents control step used four in to study XXX across of expanding portfolio our relate have or our enrolling key patient clinical to patients study sites multiple a bleeding critical France we and hemorrhage. Australia Finally centers worldwide. provide towards observational of EmboCube enroll prospective
which the will now Raul through With we our guidance, take that, fourth detailed financial to of a XXXX quarter and introduced release. turn Raul? results let financial in review our you me call press who today's over